Elotuzumab (HuLuc63)
by Jessica Langholtz
Updated: Dec 3, 2009
Updated: Dec 3, 2009
| Brand Name: | |
| Generic Name: | elotuzumab |
| Code Name: | HuLuc63 |
| Company: | Facet Biotech/Bristol-Myers Squibb |
| FDA Clinical Phase: | 1/2 |
Description:
Elotuzumab (news), a monoclonal antibody, selectively targets glycoproteins that are highly expressed on myeloma cells but not on healthy cells. In the presence of elotuzumab, myeloma cells undergo cell lysis and death. Clinical trials are currently underway to examine the activity of elotuzumab in patients with refractory or relapsed myeloma.
Clinical Trials:
For a list of clinical trials studying elotuzumab for the treatment of multiple myeloma, see ClinicalTrials.gov.
Web site for elotuzumab: http://www.facetbiotech.com/pipeline/product/elotuzumab/
Related Articles:
- Elotuzumab Combinations Show Encouraging Results In Multiple Myeloma (ASCO 2010)
- IMW 2009 – Elotuzumab And Panobinostat Clinical Trials With Velcade
- Beacon NewsFlashes – January 14, 2010
- Elotuzumab In Combination With Revlimid And Dexamethasone Shows Encouraging Results In Multiple Myeloma (ASH 2009)
- Elotuzumab Combinations Show Encouraging Results In Relapsed/Refractory Multiple Myeloma (ASH 2010)
Leave a comment